The single-cell analysis market size is expected to advance at a CAGR of 11.6% during 2021–2030, to reach $10,304.3 million by 2030. This is ascribed to the increasing pace of technological advancements and rising prevalence of cancer. Additionally, the adoption of various analytical tools and associated consumables and instruments is driving the growth of the market.
The market is also expected to be driven by an increasing focus on personalized medicine and the rising prevalence of infectious diseases. The rapid increase in the R&D for cancer by research institutes will also drive the single-cell analysis market.
The application of single-cell analysis in cancer research is to evaluate the physiology of complicated tissues at the cellular level, in order to identify the difference in gene expression and monitor the progress of tumor development, thus preventing further cell mutation.
In the APAC region, governments have initiated various funding programs to create awareness about single-cell analysis. In developing nations, such as India and China, the demand for precision medicine is increasing significantly as well.
Furthermore, the market is propelled by the increasing demand for isolation products, rising geriatric population, and surging investments in the R&D sector. Moreover, the National Cancer Registry program in India estimates that 1 in 9 Indians will develop cancer in their life and approximately 1 in 68 males will have lung cancer and 1 in 29 females will have breast cancer.
Additionally, North America holds the largest share due to a strong healthcare infrastructure, along with the existence of various tools, isolation products, and assay kits. Further, the introduction of microfluidics in single-cell analysis has improved the healthcare system and led to more investments. Furthermore, according to government reports, there were about 104,562 clinical trials going on in the area of oncology in 2022.
In addition, Europe will observe remarkable growth in the forecast period because regional countries have built a set of user-friendly tools on the Galaxy platform, to widen the access to single-cell RNA analysis platforms. Moreover, the increasing consumer awareness has led to a surge in the demand for personalized medicine, owing to the growing prevalence of cancer.
New approaches have been introduced for isolating a single living cell from a sample, such as magnetic-activated cell sorting and various microfluidic devices.
The advancements in microfluidics technologies, including cell-trapping microfluidic devices, nanowell arrays, and droplet microfluidic devices, have made studies possible at the single cell level. These devices have the capability to trap a single cell and perform various biological reactions, in order to detect the heterogeneity in cells.
Due to the recent advancements and increase in the accuracy of results, the demand has increased for single-cell analysis, including among researchers interested in single cell omics. The development of high-throughput NGS systems has enabled the study of multiomics at the single cell level. Moreover, because of the technological advancements, personalized treatment for rare diseases is also achievable.
The most-significant single-cell analysis market players are Becton, Dickinson and Company, Danaher Corporation, Merck KGaA, Thermo Fisher Scientific Inc., QIAGEN NV, Promega Corporation, and Illumina.